AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Baxter International (BAX) reported third-quarter 2026 sales of approximately $2.98 billion on Thursday, October 29, 2026, up 5% on both a reported and organic basis, with adjusted diluted EPS of $0.58, and raised its full-year 2026 outlook, according to Baxter's official release.
Regular-session close on October 29, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
Baxter Earnings Details
On a U.S. GAAP basis, net income totaled $298 million, or $0.57 per diluted share. Adjusted diluted EPS of $0.58 decreased 16% year-over-year, which the company attributed to a higher effective tax rate. The results reflect continuing operations and exclude the former Kidney Care business, which is reported as discontinued operations.
U.S. sales totaled approximately $1.6 billion, up 3% on a reported basis and 5% on an organic basis. International sales totaled approximately $1.4 billion, up 7% reported and 6% organic. Medical Products & Therapies sales were approximately $2.1 billion, up 6%, which Baxter said reflected strength in its Infusion Therapies & Platforms division, partially offset by reduced sales within Injectables. Healthcare Systems & Technologies sales were approximately $806 million, up 4%. Free cash flow was $448 million in the quarter and $705 million year-to-date.
President and CEO Andrew Hider said the quarter showed "growth across all segments and divisions globally."
Why It Matters for BAX
Baxter raised its full-year 2026 financial outlook. The company now expects reported sales growth from continuing operations of 4% to 5% (previously 3% to 4%), organic sales growth of 3% to 4% (previously 2% to 3%), and adjusted earnings from continuing operations of $2.05 to $2.15 per diluted share (previously $1.95 to $2.15).
During the quarter, the company completed a $600 million cash tender offer, retiring $864 million of debt, which it said accelerated deleveraging while supporting its investment-grade credit objectives. Hider said the company continues "to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement."
What to watch next: Baxter lists the J.P. Morgan Healthcare Conference, January 11 to 13, 2027, as its next webcasted investor event, to be made available on www.baxter.com.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
